4basebio PLC has successfully won a tender process to supply research and GMP-grade synthetic DNA for the development of RNA therapeutics and vaccines in CPI's RNA Centre of Excellence. The focus of the tender process was on the manufacture of plasmid and synthetic DNA templates, and 4basebio is set to fulfill CPI's DNA requirements for the development and scale-up of novel RNA therapeutics. The company's synthetic opDNA⢠templates offer several advantages for mRNA production, including superior transcriptional yields, no need for enzymatic linearization, reduced turnaround time, safety, and cost benefits.
Heikki Lanckriet, CEO and CSO of 4basebio, expressed delight at meeting CPI's RNA Centre of Excellence criteria for the supply of DNA templates, highlighting the growing recognition of opDNA⢠in mRNA production for clinical application. Julie Anderson, Head of RNA Centre of Excellence at CPI, emphasized the importance of including access to high-quality DNA templates produced by 4basebio for the development and manufacture of RNA therapeutics, expressing admiration for the capabilities of the 4basebio team.
4basebio is an innovation-driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performing synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The company aims to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic, and pharmacological use, as well as the development of target-specific non-viral vectors for efficient payload delivery in patients.
CPI, on the other hand, is dedicated to developing next-generation medicine manufacturing innovations to deliver tomorrow's vaccines and therapeutics. The organization offers world-leading facilities and expertise in small molecules, biologics, oligonucleotides, and complex medicines to accelerate drug development and scale-up. CPI also hosts the largest pool of RNA biomanufacturing experts in the UK and offers complementary drug delivery systems like lipid nanoparticles.
The partnership between 4basebio and CPI signifies a significant step in advancing the development and manufacture of RNA therapeutics, leveraging the expertise and capabilities of both organizations to contribute to the evolution of healthcare and drive towards a sustainable future.